Skip to main content

The effects of protocolized use of recombinant factor VIIa within a massive transfusion protocol in a civilian level I trauma center.

Publication ,  Journal Article
Morse, BC; Dente, CJ; Hodgman, EI; Shaz, BH; Nicholas, JM; Wyrzykowski, AD; Salomone, JP; Vercruysse, GA; Rozycki, GS; Feliciano, DV
Published in: Am Surg
August 2011

Despite conflicting data regarding its effectiveness, many massive transfusion protocols (MTPs) include recombinant Factor VIIa (rFVIIa) as an adjunct to hemorrhage control. Over a 3-year period, outcome data for massively transfused patients was compared based on administration of rFVIIa as part of a mature MTP. Of 228 MTP activations, 117 patients were candidates for rFVIIa, and, of these, 39 patients received rFVIIa under the MTP. Comparing patients who received rFVIIa with those who did not based on initial packed red blood cell (PRBC) transfusion requirements, there was no difference in mortality for transfusions ≤ 20 units (25 vs 24%, 24-hour; 25 vs 42%, 30-day) or 21 to 30 units (33 vs 47%, 24-hour; 55 vs 50%, 30-day). For initial requirement ≥ 30 units of PRBCs, 24-hour mortality (26 vs 64%, P = 0.02) was significantly decreased in patients that received rFVIIa (n = 19) compared with those who did not (n = 17). These mortality differences were not maintained at 30 days (68 vs 71%). rFVIIa had minimal clinical impact on outcomes for patients requiring less than 30 units of PRBCs. For patients transfused more than 30 units of PRBCs, differences in 24-hour and 30-day mortality suggest that rFVIIa converted early deaths from exsanguination to late deaths from multiorgan failure.

Duke Scholars

Published In

Am Surg

EISSN

1555-9823

Publication Date

August 2011

Volume

77

Issue

8

Start / End Page

1043 / 1049

Location

United States

Related Subject Headings

  • Wounds and Injuries
  • Treatment Outcome
  • Trauma Centers
  • Time Factors
  • Survival Analysis
  • Surgery
  • Risk Assessment
  • Recombinant Proteins
  • Prospective Studies
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Morse, B. C., Dente, C. J., Hodgman, E. I., Shaz, B. H., Nicholas, J. M., Wyrzykowski, A. D., … Feliciano, D. V. (2011). The effects of protocolized use of recombinant factor VIIa within a massive transfusion protocol in a civilian level I trauma center. Am Surg, 77(8), 1043–1049.
Morse, Bryan C., Christopher J. Dente, Erica I. Hodgman, Beth H. Shaz, Jeffrey M. Nicholas, Amy D. Wyrzykowski, Jeffrey P. Salomone, Gary A. Vercruysse, Grace S. Rozycki, and David V. Feliciano. “The effects of protocolized use of recombinant factor VIIa within a massive transfusion protocol in a civilian level I trauma center.Am Surg 77, no. 8 (August 2011): 1043–49.
Morse BC, Dente CJ, Hodgman EI, Shaz BH, Nicholas JM, Wyrzykowski AD, et al. The effects of protocolized use of recombinant factor VIIa within a massive transfusion protocol in a civilian level I trauma center. Am Surg. 2011 Aug;77(8):1043–9.
Morse BC, Dente CJ, Hodgman EI, Shaz BH, Nicholas JM, Wyrzykowski AD, Salomone JP, Vercruysse GA, Rozycki GS, Feliciano DV. The effects of protocolized use of recombinant factor VIIa within a massive transfusion protocol in a civilian level I trauma center. Am Surg. 2011 Aug;77(8):1043–1049.

Published In

Am Surg

EISSN

1555-9823

Publication Date

August 2011

Volume

77

Issue

8

Start / End Page

1043 / 1049

Location

United States

Related Subject Headings

  • Wounds and Injuries
  • Treatment Outcome
  • Trauma Centers
  • Time Factors
  • Survival Analysis
  • Surgery
  • Risk Assessment
  • Recombinant Proteins
  • Prospective Studies
  • Male